COVID-19 z-bio 2021-02-14 339

　　According to an article recently published in the journal Cochrane Review, hydroxychloroquine cannot reduce COVID-19 deaths, and may not reduce the number of people who need ventilators. In addition, they pointed out that new trials of hydroxychloroquine or chloroquine for COVID-19 should not be started.

　　Authors from India, South Africa and the United Kingdom (LSTM, University of Liverpool, Liverpool Royal Liverpool University Hospital) conducted a systematic review of studies on the use of chloroquine or hydroxychloroquine to treat or prevent COVID-19 disease.

　　The public's demand for COVID-19 therapy has stimulated speculation that the drug may be effective, but this is based on unreliable research that does not meet the inclusion criteria of this review. About a year ago, US President Trump declared that chloroquine was a "game changer", causing global demand and chaos. Many scientists quickly organized large-scale experiments, none of which showed valid evidence. This review summarizes these experiments.

　　The authors of this review include 14 related studies: 12 studies of chloroquine or hydroxychloroquine for the treatment of COVID-19 in 8569 adults; and 12 studies. And two studies using hydroxychloroquine to prevent COVID-19 in 3346 adults who have been exposed to the virus but have no symptoms of infection. The included studies are from China, Brazil, Egypt, Iran, Spain, the United Kingdom, and North America; a global study was conducted in 30 countries/regions, some of which were partially funded by pharmaceutical companies that manufacture hydroxychloroquine.

　　Senior author Dr. Tom Fletcher said: "This review will definitely delimit the use of this drug to treat COVID-19, but some countries and medical institutions are still stuck in the early hype and prescription process. We hope this review Can help these practices end as soon as possible."